Mostrar el registro sencillo del ítem

dc.contributor.author
Cardinali, Daniel Pedro  
dc.contributor.author
Cano, Pilar  
dc.contributor.author
Jiménez Ortega, Vanesa  
dc.contributor.author
Esquifino, Ana I.  
dc.date.available
2023-03-29T12:12:32Z  
dc.date.issued
2011-04  
dc.identifier.citation
Cardinali, Daniel Pedro; Cano, Pilar; Jiménez Ortega, Vanesa; Esquifino, Ana I.; Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications; Karger; Neuroendocrinology; 93; 3; 4-2011; 133-142  
dc.identifier.issn
0028-3835  
dc.identifier.uri
http://hdl.handle.net/11336/191939  
dc.description.abstract
Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities, and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep-wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequelae in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbidities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease, merits further investigation.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Karger  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
CIRCADIAN RHYTHMS  
dc.subject
MELATONERGIC AGONISTS  
dc.subject
MELATONIN  
dc.subject
METABOLIC SYNDROME  
dc.subject.classification
Fisiología  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Melatonin and the metabolic syndrome: Physiopathologic and therapeutical implications  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-03-28T14:20:17Z  
dc.identifier.eissn
1423-0194  
dc.journal.volume
93  
dc.journal.number
3  
dc.journal.pagination
133-142  
dc.journal.pais
Suiza  
dc.journal.ciudad
Basel  
dc.description.fil
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Ciencias Fisiológicas. Cátedra de Fisiologia; Argentina  
dc.description.fil
Fil: Cano, Pilar. Universidad Complutense de Madrid; España  
dc.description.fil
Fil: Jiménez Ortega, Vanesa. Universidad Complutense de Madrid; España  
dc.description.fil
Fil: Esquifino, Ana I.. Universidad Complutense de Madrid; España  
dc.journal.title
Neuroendocrinology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.karger.com/Article/Abstract/324699  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1159/000324699